CPI-613 (devimistat) received Orphan Drug designation from FDA for the treatment of soft tissue sarcoma.
Exact Sciences Corp. and Thrive Earlier Detection Corp. have entered into a definitive agreement under which Exact Sciences will acquire Thrive for cash and stock consideration of up to $2.15 billion.
EQRx has licensed two late-stage immuno-oncology agents from CStone Pharmaceuticals. The licensing agreement covers sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1).
The StrataNGS test has received coverage under Medicare by Palmetto GBA, a Medicare Administrative Contractor, for patients with advanced stages (III or IV), recurrent, relapsed, refractory, and/or metastatic solid tumors.
FDA has approved FoundationOne Liquid CDx for three new companion diagnostic indications to help match patients who may benefit from treatment with specific FDA-approved targeted therapies.
Venclexta (venetoclax) has received FDA approval in combination with azacitidine, decitabine, or low-dose cytarabine (LDAC) for newly-diagnosed acute myeloid leukemia in adults 75 years or older, or who have comorbidities precluding intensive induction chemotherapy.
Tagrisso receives FDA Priority Review for adjuvant treatment of early-stage EGFR-mutated lung cancer
Tagrisso (osimertinib) has received acceptance for its supplemental New Drug Application and has also been granted Priority Review by FDA for the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent.
Keytruda (pembrolizumab) has received an expanded label use from FDA as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.
The United Kingdom plans to join two international initiatives that will allow pharmaceutical companies to submit medicines to be reviewed by several countries at the same time, pooling resources and allowing patients to benefit from earlier access.
MD Anderson Cancer Center and Allogene Therapeutics Inc. have entered into a five-year collaboration agreement for the preclinical and clinical investigation of AlloCAR T candidates across Allogene's portfolio of hematologic and solid tumors.
